Substance / Medication

Sulfasalazine

Overview

Active Ingredient
sulfasalazine
RxNorm CUI
9524

Indications

Sulfasalazine tablets are indicated: in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; and for the prolongation of the remission period between acute attacks of ulcerative colitis

Labeler: REMEDYREPACK INC.Updated: 2026-01-28T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Sulfasalazine tablets are contraindicated in: Patients with intestinal or urinary obstruction, Patients with porphyria as sulfonamides have been reported to precipitate an acute attack, Patients hypersensitive to sulfasalazine, its metabolites, sulfonamides, or salicylates.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

84 trials linked to this intervention

84
Total Trials
30
Recruiting
15
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Meta-analysis and systematic review on Sulfasalazine/5-ASA use during pregnancy: Impact on neonatal and pregnancy outcomes.
Asthana Rashi, Hamandi Bassem, Brnabic Alan et al. · Reprod Toxicol · 2025
PMID: 40334871Meta-Analysis
Sulfasalazine for ankylosing spondylitis.
Chen Junmin, Lin Shaopeng, Liu Chao · Cochrane Database Syst Rev · 2014
PMID: 25427435Meta-AnalysisFull text (PMC)
Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials.
Chen Junmin, Liu Chao · J Rheumatol · 2006
PMID: 16583475Meta-Analysis
Sulfasalazine for ankylosing spondylitis.
Chen J, Liu C · Cochrane Database Syst Rev · 2005
PMID: 15846731Meta-Analysis
Folic acid and sulfasalazine for colorectal carcinoma chemoprevention in patients with ulcerative colitis: the old and new evidence.
Diculescu Mircea, Ciocîrlan Mihai, Ciocîrlan Mirela et al. · Rom J Gastroenterol · 2003
PMID: 14726972Meta-Analysis
Sulfasalazine for the management of juvenile rheumatoid arthritis.
Brooks C D · J Rheumatol · 2001
PMID: 11327261Meta-Analysis
Sulfasalazine for rheumatoid arthritis.
Suarez-Almazor M E, Belseck E, Shea B et al. · Cochrane Database Syst Rev · 2000
PMID: 10796400Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Sulfasalazine (substance)
SNOMED CT
387248006
UMLS CUI
C0036078
RxNorm CUI
9524
Labeler
REMEDYREPACK INC.

Clinical Data

This intervention maps to 8 entities in the Ltrl knowledge graph.

3
Conditions
2
Biomarkers
1
Specialists
0
Symptoms
84
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.